BICO Group AB (publ) (BCCOY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BICO Group AB (publ) (BCCOY) trades at $0.50 with AI Score 46/100 (Grade C). BICO Group AB (publ) operates as a bio convergence company, providing laboratory solutions and bioautomation products to medical, pharmaceutical, and cosmetic industries. Market cap: $141.15M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for BCCOY: BCCOY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BCCOY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BCCOY: the 1 perspectives are evenly split.
How is this calculated? →BICO Group AB (publ) (BCCOY) Healthcare & Pipeline Overview
BICO Group AB (publ) is a bio convergence company providing 3D bioprinting, bioautomation, and laboratory solutions to the medical, pharmaceutical, and cosmetic industries. With a focus on tissue engineering and diagnostics, BICO serves a global market, offering tools and services for regulatory testing and advanced research applications.
What Is the Investment Thesis for BCCOY?
BICO Group AB (publ) presents a notable research candidate within the bio convergence space. The company's focus on 3D bioprinting and automation solutions caters to the growing demand for advanced tools in the medical, pharmaceutical, and cosmetic industries. Key value drivers include the expansion of its product portfolio and penetration into new geographic markets. The company's gross margin stands at 45.3%. However, the company's negative profit margin of -70.2% and a high beta of 2.77 indicate significant risk. Upcoming catalysts include potential partnerships with pharmaceutical companies and expansion of its bioautomation segment. Investors should monitor the company's ability to achieve profitability and manage its operational costs.
Based on FMP financials and quantitative analysis
BCCOY Key Highlights
- BICO Group AB (publ) operates in the bio convergence space, merging biology and technology.
- The company's gross margin is 45.3%, indicating a strong ability to control production costs.
- BICO serves the medical, pharmaceutical, and cosmetic industries, providing diversification across healthcare sectors.
- The company's beta is 2.77, indicating high volatility compared to the market.
- BICO Group AB (publ) has a negative profit margin of -70.2%, reflecting ongoing challenges in achieving profitability.
Who Are BCCOY's Competitors?
BCCOY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACMLF Ascom Holding AG | $4.37 | +0.00% | $149.28M | 49 |
| BRIBF Brii Biosciences Limited | $0.15 | +0.00% | $107.82M | 46 |
| CYBQF CYBERDYNE Inc. | $1.30 | +0.00% | $173.46M | 58 |
| MLLCF Molecular Partners AG | $3.60 | +0.00% | $135.04M | 43 |
| NDTP NDT Pharmaceuticals Inc. | $0.46 | +0.00% | $73.51M | 42 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.19 | +0.00% | $17.66M | 73 |
| DCTH Delcath Systems, Inc. | $13.20 | +2.25% | $455.69M | 73 |
| SSII SS Innovations International, Inc. | $3.78 | -4.06% | $756.50M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BCCOY's Key Strengths?
- Innovative 3D bioprinting technology
- Strong presence in the research and pharmaceutical sectors
- Comprehensive product portfolio
- Strategic partnerships with leading institutions
What Are BCCOY's Weaknesses?
- Negative profit margin
- High beta indicating high volatility
- Limited brand recognition compared to larger competitors
- Dependence on research grants and funding
What Could Drive BCCOY Stock Higher?
- Expansion of product portfolio with new bioinks and bioprinting technologies.
- Potential partnerships with pharmaceutical companies for drug discovery applications (2026-Q4).
- Geographic expansion into the Asia-Pacific market.
- Publication of clinical trial results using BICO's technology (2026-Q3).
- Increased adoption of BICO's solutions in personalized medicine.
What Are the Key Risks for BCCOY?
- Financial-distress signal — its Altman Z-Score of -2.91 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-51.8%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established players in the laboratory solutions and bioautomation markets.
- Negative profit margin and high operational costs.
- Economic downturn affecting research funding and capital expenditures.
- Stringent regulatory requirements and compliance costs.
- Currency risk due to fluctuations in the Swedish Krona (SEK) against the U.S. dollar (USD).
What Are the Growth Opportunities for BCCOY?
- Expansion into Personalized Medicine: BICO can leverage its 3D bioprinting technology to create personalized medical solutions, such as patient-specific implants and tissues. The personalized medicine market is projected to reach $2.4 billion by 2028, offering significant growth potential. BICO's ability to tailor solutions to individual patient needs provides a competitive advantage. This expansion requires strategic partnerships with hospitals and research institutions.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop new drug screening platforms and accelerate drug discovery processes. The pharmaceutical industry is increasingly adopting advanced technologies to reduce development costs and timelines. BICO's laboratory solutions can enhance drug screening accuracy and efficiency. These partnerships can provide BICO with recurring revenue streams and market validation.
- Geographic Expansion in Asia-Pacific: Expanding its presence in the Asia-Pacific region, where demand for advanced healthcare solutions is growing rapidly. The region's aging population and increasing healthcare expenditure create opportunities for BICO's products and services. Establishing local partnerships and distribution networks is crucial for successful market entry. This expansion can significantly increase BICO's revenue and global market share.
- Development of Advanced Bioinks: Investing in the development of advanced bioinks with improved biocompatibility and functionality. Bioinks are essential for 3D bioprinting and play a critical role in tissue engineering and regenerative medicine. BICO's ability to create bioinks that mimic the natural extracellular matrix can enhance the success of bioprinted tissues and organs. This innovation can attract new customers and solidify BICO's position as a leader in the bio convergence space.
- Integration of Artificial Intelligence (AI): Integrating AI and machine learning technologies into its bioprinting and automation platforms to improve efficiency and accuracy. AI can optimize printing parameters, predict tissue behavior, and automate laboratory processes. This integration can reduce human error and accelerate research and development timelines. The AI in healthcare market is expected to grow significantly, offering BICO a competitive edge.
What Opportunities Does BCCOY Have?
- Expansion into personalized medicine
- Growing demand for 3D bioprinting in drug discovery
- Geographic expansion in Asia-Pacific
- Development of advanced bioinks
What Threats Does BCCOY Face?
- Intense competition from established players
- Stringent regulatory requirements
- Economic downturn affecting research funding
- Technological obsolescence
What Are BCCOY's Competitive Advantages?
- Proprietary Technology: BICO's patented 3D bioprinting technology and bioinks provide a competitive advantage.
- Established Customer Base: The company has built a strong customer base in the research, pharmaceutical, and healthcare sectors.
- Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies enhance BICO's market position.
- Comprehensive Product Portfolio: BICO offers a wide range of products and services, providing a one-stop solution for customers.
What Does BCCOY Do?
BICO Group AB (publ), formerly known as Cellink AB, was founded in 2016 and is headquartered in Gothenburg, Sweden. The company operates as a bio convergence entity, offering solutions that bridge biology and technology. BICO serves the medical, pharmaceutical, and cosmetic industries across North America, Europe, Asia, and internationally. The company is structured into two primary segments: Laboratory Solutions and Bioautomation. The Laboratory Solutions segment provides 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments. It also offers related consumables such as bioinks, reagents, microscope lenses, software, and 3D reconstructed human tissues, which are used in regulatory testing. This segment also provides services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology. The Bioautomation segment delivers precision dispensing and biosensor technology to industrial customers, as well as diagnostics automation and advanced robotics solutions for the medical and diagnostic sectors. BICO's product offerings also include core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions.
What Products and Services Does BCCOY Offer?
- Develops and sells 3D bioprinters for tissue engineering and regenerative medicine.
- Offers hybrid microscopes for advanced cell imaging and analysis.
- Provides single-cell dispensing instruments for precise cell handling.
- Manufactures liquid handling instruments for laboratory automation.
- Supplies bioinks, reagents, and other consumables for bioprinting applications.
- Offers services in 3D cell culture, tissue imaging, and digital pathology.
- Provides precision dispensing and biosensor technology for industrial customers.
- Offers diagnostics automation and advanced robotics solutions for the medical and diagnostic industries.
How Does BCCOY Make Money?
- Sells 3D bioprinters, microscopes, and related instruments to research institutions, pharmaceutical companies, and hospitals.
- Generates revenue from the sale of consumables such as bioinks and reagents.
- Provides services in 3D cell culture, tissue imaging, and digital pathology.
- Offers automation solutions to industrial and medical customers.
What Industry Does BCCOY Operate In?
BICO Group AB (publ) operates within the medical devices industry, which is experiencing growth driven by technological advancements and increasing demand for personalized medicine. The market for 3D bioprinting is expanding, with applications in drug discovery, tissue engineering, and regenerative medicine. BICO competes with companies such as ACMLF, BRIBF, CYBQF, MLLCF, and NDTP, which offer various laboratory solutions and automation technologies. The industry is characterized by high research and development costs and stringent regulatory requirements. BICO's bio convergence approach positions it to capitalize on the convergence of biology and technology, addressing the needs of the medical, pharmaceutical, and cosmetic industries.
Who Are BCCOY's Key Customers?
- Research institutions conducting tissue engineering and regenerative medicine research.
- Pharmaceutical companies developing new drugs and therapies.
- Hospitals and medical centers performing tissue repair and replacement procedures.
- Cosmetic companies developing and testing new products.
Company Profile
BICO Group AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Gothenburg, SE. The company is led by CEO Maria Forss. BCCOY has traded publicly since 2021.
ROE -52%Key Financial Metrics
Return on equity for BICO Group AB (publ) stands at -51.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -81.4%, the inverse of the P/E and a quick read on earnings relative to price.
BCCOY Valuation & Market Position
With a $141.15M market cap, BICO Group AB (publ) sits in the micro-cap segment of the market. Relative to its peer group, BCCOY's quantitative score of 46/100 is roughly in line with the peer average of 48/100.
Quarterly Financial Performance: BICO Group AB (publ)
Revenue for BICO Group AB (publ) came in at $329.9M during Q1 2026, a 25.4% contraction versus the preceding quarter. The company recorded a net loss of $131.3M, with diluted EPS of $-0.46. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BCCOY averaged $-0.72 in diluted EPS.
F-Score 5/9Financial Health
BICO Group AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.91 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project BICO Group AB (publ) revenue of about $1.57B for fiscal 2026, with EPS near $0.00. The estimate reflects 3 contributing analysts.
BCCOY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative 3D bioprinting technology
- Strong presence in the research and pharmaceutical sectors
- Comprehensive product portfolio
- Strategic partnerships with leading institutions
Bear Case
- Negative profit margin
- High beta indicating high volatility
- Limited brand recognition compared to larger competitors
- Dependence on research grants and funding
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $330M | -$131M | -$0.46 |
| Q4 2025 | $442M | -$58M | -$0.20 |
| Q3 2025 | $381M | -$603M | -$2.16 |
| Q2 2025 | $324M | -$184M | -$0.07 |
Based on FMP financials and quantitative analysis
BCCOY Latest News
No recent news available for BCCOY.
BCCOY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCCOY.
Price Targets
Wall Street price target analysis for BCCOY.
BCCOY MoonshotScore
What does this score mean?
The MoonshotScore rates BCCOY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Maria Forss
CEO
Maria Forss serves as the CEO of BICO Group AB (publ). Her background includes extensive experience in managing and scaling technology-driven companies. She has a proven track record in strategic leadership and operational excellence. She is responsible for overseeing BICO's global operations and driving the company's growth strategy. Her expertise lies in biotechnology and business development, which is crucial for BICO's expansion and innovation in the bio convergence space.
Track Record: Under Maria Forss's leadership, BICO Group AB (publ) has focused on expanding its product portfolio and strengthening its presence in key markets. She has overseen strategic acquisitions and partnerships to enhance the company's technological capabilities and market reach. Her focus on innovation and customer satisfaction has contributed to BICO's growth and success in the bio convergence industry.
BICO Group AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. BCCOY is an ADR, meaning it allows U.S. investors to invest in BICO Group AB (publ) without directly dealing with the Gothenburg Stock Exchange. The ADR is denominated in U.S. dollars, simplifying transactions and reporting for U.S. investors.
- Home Market Ticker: Gothenburg Stock Exchange, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BCCO
BCCOY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and transparency compared to exchange-listed companies. These companies may be newly established, financially distressed, or have chosen not to list on a major exchange for various reasons.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of publicly available financial information makes it difficult to assess the company's financial health and performance.
- Low Liquidity: Low trading volume and wide bid-ask spreads can make it challenging to buy or sell shares without impacting the price.
- Regulatory Uncertainty: OTC stocks are subject to less regulatory oversight compared to exchange-listed stocks, increasing the risk of fraud and manipulation.
- Valuation Challenges: The limited information available makes it difficult to accurately value the company.
- Potential for Delisting: BCCOY could be delisted from the OTC market if it fails to meet certain requirements.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established Business Operations: BICO Group AB (publ) has been in operation since 2016, indicating a track record of business activity.
- Global Presence: The company operates in North America, Europe, Asia, and internationally, suggesting a broad market reach.
- Audited Financials: While the disclosure level is unknown, any available audited financial statements would be a positive signal.
- Partnerships: Any partnerships with reputable organizations would indicate credibility.
- Industry Recognition: Awards or recognition from industry associations would be a positive sign.
Common Questions About BCCOY (Healthcare)
What does BICO Group AB (publ) do?
BICO Group AB (publ) operates as a bio convergence company, providing laboratory solutions and bioautomation products to the medical, pharmaceutical, and cosmetic industries. The company's core offerings include 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and related consumables such as bioinks and reagents. BICO's solutions are used in tissue engineering, regenerative medicine, drug discovery, and diagnostics, serving a global market with a focus on innovation and technological advancement in the healthcare sector.
What are the main risks for BCCOY?
The main risks for BICO Group AB (publ) include intense competition in the laboratory solutions and bioautomation markets, which could impact market share and profitability. The company's negative profit margin and high operational costs pose a challenge to achieving sustainable profitability. Economic downturns could affect research funding and capital expenditures, reducing demand for BICO's products and services. Stringent regulatory requirements and compliance costs could also increase expenses and delay product development. Currency risk due to fluctuations in the Swedish Krona (SEK) against the U.S. dollar (USD) could impact revenue and earnings.
What are the key factors to evaluate for BCCOY?
BICO Group AB (publ) (BCCOY) holds an AI score of 46/100 (low). Not financial advice.
How frequently does BCCOY data refresh on this page?
BCCOY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BCCOY's recent stock price performance?
BICO Group AB (publ) (BCCOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative 3D bioprinting technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BCCOY overvalued or undervalued right now?
Valuing BICO Group AB (publ) (BCCOY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BCCOY?
Before investing in BICO Group AB (publ) (BCCOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BCCOY to a portfolio?
Key strength of BICO Group AB (publ) (BCCOY): Innovative 3D bioprinting technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- Analyst consensus is not available due to limited coverage.
- OTC market data may be less reliable than exchange-listed data.